Effect of zoledronic acid dosing every 3 months in patients with prostate cancer with skeletal metastases: A multicenter prospective exploratory study with matched historical controls
Akihiro Yano M.D., Ph.D.
Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Search for more papers by this authorYoshiaki Arai M.D.
Department of Urology, Nishi-Omiya Hospital, Saitama, Japan
Search for more papers by this authorSachi Kitayama M.D.
Department of Urology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan
Search for more papers by this authorYukihiro Otsuka M.D., Ph.D.
Department of Urology, Omori Red Cross Hospital, Tokyo, Japan
Search for more papers by this authorSuguru Shirotake M.D., Ph.D.
Department of Urologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan
Search for more papers by this authorSatoru Kawakami M.D., Ph.D.
Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Search for more papers by this authorAkihiro Yano M.D., Ph.D.
Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Search for more papers by this authorYoshiaki Arai M.D.
Department of Urology, Nishi-Omiya Hospital, Saitama, Japan
Search for more papers by this authorSachi Kitayama M.D.
Department of Urology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan
Search for more papers by this authorYukihiro Otsuka M.D., Ph.D.
Department of Urology, Omori Red Cross Hospital, Tokyo, Japan
Search for more papers by this authorSuguru Shirotake M.D., Ph.D.
Department of Urologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan
Search for more papers by this authorSatoru Kawakami M.D., Ph.D.
Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Search for more papers by this authorConflict of interest
None declared.
Supporting Information
| Filename | Description |
|---|---|
| iju13703-sup-0001-sm_f1.epsimage/eps, 85.7 KB | Figure S1. Comparison of SRE-free surivival rate between patients treated with pADT plus ZA every 3 months and those treated with pADT alone in the propensity-matched cohort. |
| iju13703-sup-0002-sm_t1.xlsxMS Excel, 12 KB | Table S1. Patient characteristics in the entire cohort. |
| iju13703-sup-0003-sm_t2.xlsxMS Excel, 11.8 KB | Table S2. Patient characteristics in the propensity-matched cohort. |
| iju13703-sup-0004-sm_t3.xlsxMS Excel, 11.1 KB | Table S3. Univariate and multivariate analyses of baseline parameters predictive of PSA-PFS in the entire cohort. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Gnant M, Clézardin P. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat. Rev. 2012; 38: 407–15.
- 2Kamba T, Kamoto T, Maruo S et al. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. Int. J. Clin. Oncol. 2017; 22: 166–73.
- 3Ueno S, Mizokami A, Fukagai T et al. Efficacy of Combined Androgen Blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (Zoledronic Acid/Androgen Blockade Trial on Prostate Cancer) study. Anticancer Res. 2013; 33: 3837–44.
- 4Hortobagyi GN, Van Poznak C, Harker WG et al. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol. 2017; 3: 906–12.
- 5Shapiro CL, Moriarty JP, Dusetzina S et al. Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (Alliance). J. Clin. Oncol. 2017; 35: 3949–55.
- 6Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 2008; 26: 1148–59.
